tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
RIBOMIC Reports Sustained Efficacy of Umedaptanib Pegol in Achondroplasia Trial
PremiumCompany AnnouncementsRIBOMIC Reports Sustained Efficacy of Umedaptanib Pegol in Achondroplasia Trial
3M ago
Ribomic Inc. Reports Continued Losses in Q1 2025
Premium
Company Announcements
Ribomic Inc. Reports Continued Losses in Q1 2025
4M ago
RIBOMIC to Launch Phase III Trial for Achondroplasia Drug in 2026
Premium
Company Announcements
RIBOMIC to Launch Phase III Trial for Achondroplasia Drug in 2026
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100